Global onychomycosis treatment market will reach $5,787.4 million by 2031, growing by 7.9% annually over 2021-2031, driven by the increasing prevalence of chronic medical ailments, the growing geriatric population, improved therapies and preventative solutions, and the rising healthcare expenditure.
Highlighted with 80 tables and 72 figures, this 150-page report 鈥淕lobal Onychomycosis Treatment 麻豆原创 2021-2031 by Onychomycosis Type (Distal Subungual, White Superficial, Proximal Subungual, Candidal, Others), Treatment Type (Drug Treatment, Laser Therapy, Photodynamic Therapy, Others), Distribution Channel (Hospitals and Clinics, Online Stores, Retail Pharmacies, Others), and Region: Trend Forecast and Growth Opportunity鈥� is based on a comprehensive research of the entire global onychomycosis treatment market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2018-2021 and provides forecast from 2022 till 2031 with 2021 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
鈥� 麻豆原创 Structure
鈥� Growth Drivers
鈥� Restraints and Challenges
鈥� Emerging Product Trends & 麻豆原创 Opportunities
鈥� Porter鈥檚 Fiver Forces
The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and the Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify global onychomycosis treatment market in every aspect of the classification from perspectives of Onychomycosis Type, Treatment Type, Distribution Channel, and Region.
Based on Onychomycosis Type, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
鈥� Distal Subungual Onychomycosis
鈥� White Superficial Onychomycosis
鈥� Proximal Subungual Onychomycosis
鈥� Candidal Onychomycosis
鈥� Other Onychomycosis Types
Based on Treatment Type, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
鈥� Drug Treatment
鈥� Laser Therapy
鈥� Photodynamic Therapy
鈥� Other Therapies
By Distribution Channel, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
鈥� Hospitals and Clinics
鈥� Online Stores
鈥� Retail Pharmacies
鈥� Other Distribution Channels
Geographically, the following regions together with the listed national/local markets are fully investigated:
鈥� North America (U.S., Canada, and Mexico)
鈥� Europe (Germany, UK, France, Spain, Italy, Netherlands, Rest of Europe; Rest of Europe is further segmented into Russia, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
鈥� APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
鈥� South America (Brazil, Chile, Argentina, Rest of South America)
鈥� MEA (UAE, Saudi Arabia, South Africa, Other Nations)
For each aforementioned region and country, detailed analysis and data for annual revenue ($ mn) are available for 2021-2031. The breakdown of all regional markets by Onychomycosis Type, Treatment Type and Distribution Channel over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Selected Key Players:
Bausch Health Companies Inc.
Bayer AG
Cipla Ltd
Dr. Reddys Laboratories Ltd
Galderma SA
GlaxoSmithKline PLC
Johnson & Johnson
Lumenis Ltd
Medimetriks Pharmaceuticals Inc.
Moberg Pharma AB
Novartis AG
Pfizer Inc.
Sanofi SA
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
1 Introduction 9
1.1 Industry Definition and Research Scope 9
1.1.1 Industry Definition 9
1.1.2 Research Scope 10
1.2 Research Methodology 13
1.2.1 Overview of 麻豆原创 Research Methodology 13
1.2.2 麻豆原创 Assumption 14
1.2.3 Secondary Data 14
1.2.4 Primary Data 14
1.2.5 Data Filtration and Model Design 15
1.2.6 麻豆原创 Size/Share Estimation 16
1.2.7 Research Limitations 17
1.3 Executive Summary 18
2 麻豆原创 Overview and Dynamics 20
2.1 麻豆原创 Size and Forecast 20
2.1.1 Impact of COVID-19 on World Economy 21
2.1.2 Impact of COVID-19 on the 麻豆原创 23
2.2 Major Growth Drivers 25
2.3 麻豆原创 Restraints and Challenges 32
2.4 Emerging Opportunities and 麻豆原创 Trends 35
2.5 Porter鈥檚 Fiver Forces Analysis 39
3 Segmentation of Global 麻豆原创 by Onychomycosis Type 43
3.1 麻豆原创 Overview by Onychomycosis Type 43
3.2 Distal Subungual Onychomycosis 45
3.3 White Superficial Onychomycosis 46
3.4 Proximal Subungual Onychomycosis 47
3.5 Candidal Onychomycosis 48
3.6 Other Onychomycosis Types 49
4 Segmentation of Global 麻豆原创 by Treatment Type 50
4.1 麻豆原创 Overview by Treatment Type 50
4.2 Drug Treatment 52
4.3 Laser Therapy 53
4.4 Photodynamic Therapy 54
4.5 Other Therapies 55
5 Segmentation of Global 麻豆原创 by Distribution Channel 56
5.1 麻豆原创 Overview by Distribution Channel 56
5.2 Hospitals and Clinics 58
5.3 Online Stores 59
5.4 Retail Pharmacies 60
5.5 Other Distribution Channels 61
6 Segmentation of Global 麻豆原创 by Region 62
6.1 Geographic 麻豆原创 Overview 2021-2031 62
6.2 North America 麻豆原创 2021-2031 by Country 66
6.2.1 Overview of North America 麻豆原创 66
6.2.2 U.S. 70
6.2.3 Canada 73
6.2.4 Mexico 75
6.3 European 麻豆原创 2021-2031 by Country 77
6.3.1 Overview of European 麻豆原创 77
6.3.2 Germany 81
6.3.3 U.K. 83
6.3.4 France 85
6.3.5 Spain 87
6.3.6 Italy 89
6.3.7 Netherlands 91
6.3.8 Rest of European 麻豆原创 93
6.4 Asia-Pacific 麻豆原创 2021-2031 by Country 95
6.4.1 Overview of Asia-Pacific 麻豆原创 95
6.4.2 Japan 99
6.4.3 China 102
6.4.4 Australia 104
6.4.5 India 106
6.4.6 South Korea 108
6.4.7 Rest of APAC Region 110
6.5 South America 麻豆原创 2021-2031 by Country 112
6.5.1 Argentina 115
6.5.2 Brazil 117
6.5.3 Chile 119
6.5.4 Rest of South America 麻豆原创 121
6.6 MEA 麻豆原创 2021-2031 by Country 122
6.6.1 UAE 125
6.6.2 Saudi Arabia 127
6.6.3 South Africa 129
6.6.4 Other National 麻豆原创s 131
7 Competitive Landscape 132
7.1 Overview of Key Vendors 132
7.2 New Product Launch, Partnership, Investment, and M&A 135
7.3 Company Profiles 136
Bausch Health Companies Inc. 136
Bayer AG 138
Cipla Ltd 139
Dr. Reddys Laboratories Ltd 140
Galderma SA 141
GlaxoSmithKline PLC 142
Johnson & Johnson 143
Lumenis Ltd 144
Medimetriks Pharmaceuticals Inc. 145
Moberg Pharma AB 146
Novartis AG 147
Pfizer Inc. 148
Sanofi SA 149
RELATED REPORTS 150
Selected Key Players:
Bausch Health Companies Inc.
Bayer AG
Cipla Ltd
Dr. Reddys Laboratories Ltd
Galderma SA
GlaxoSmithKline PLC
Johnson & Johnson
Lumenis Ltd
Medimetriks Pharmaceuticals Inc.
Moberg Pharma AB
Novartis AG
Pfizer Inc.
Sanofi SA
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
听
听
*If Applicable.